Donna’s Path to Possible With Jakafi® (ruxolitinib) скачать в хорошем качестве

Donna’s Path to Possible With Jakafi® (ruxolitinib)

Donna was concerned when her flourishing career as a motivational speaker was interrupted by an unexpected decline in her health. After blood tests showed that her platelet count and hematocrit were abnormally high, Donna was diagnosed with a rare, chronic blood cancer called polycythemia vera (PV). Her oncologist prescribed hydroxyurea (HU), but Donna found she could not tolerate it. She was hopeful when her oncologist changed her treatment to Jakafi® (ruxolitinib). Jakafi is a prescription medicine used to treat adults with PV who have already taken a medicine called HU and it did not work well enough or they could not tolerate it. Selected Safety Information Jakafi can cause serious side effects including low blood counts and infection. Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of myelofibrosis and PV include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects. To learn more about these and other risks, please read the Important Safety Information at https://www.jakafi.com/. Please see the Full Prescribing Information at https://www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463. Sponsored by Incyte Corporation. Jakafi is a registered trademark of Incyte. © 2022, Incyte Corporation. MAT-JAK-02969 01/22